Pozen has filed a motion in a federal court to prevent generics maker Par Pharmaceutical from launching a generic version of its migraine combination treatment, Treximet (sumatriptan and naproxen sodium), in the US marketplace. Treximet is marketed in the US by GlaxoSmithKline.
Pozen says that it believes Par, as first-filer, has the 180 days of market exclusivity for the product and could...